New combo therapy aims to shrink head and neck tumors that resist standard treatment
Disease control
Recruiting now
This study tests whether adding an experimental drug called ficerafusp alfa to the immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1-positive head and neck cancer that has spread or returned. About 650 adults will be randomly assig…
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC